WO2008096779A1 - Ｃ７０含有リポソームおよびその製造方法、並びにその利用 - Google Patents

Ｃ７０含有リポソームおよびその製造方法、並びにその利用 Download PDF

Info

Publication number
WO2008096779A1
WO2008096779A1 PCT/JP2008/051928 JP2008051928W WO2008096779A1 WO 2008096779 A1 WO2008096779 A1 WO 2008096779A1 JP 2008051928 W JP2008051928 W JP 2008051928W WO 2008096779 A1 WO2008096779 A1 WO 2008096779A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
liposome
producing
containing liposome
fullerene
Prior art date
Application number
PCT/JP2008/051928
Other languages
English (en)
French (fr)
Inventor
Atsushi Ikeda
Jun-Ichi Kikuchi
Original Assignee
National University Corporation NARA Institute of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation NARA Institute of Science and Technology filed Critical National University Corporation NARA Institute of Science and Technology
Priority to JP2008557136A priority Critical patent/JP5334170B2/ja
Priority to AT08704499T priority patent/ATE507835T1/de
Priority to EP08704499A priority patent/EP2123288B1/en
Priority to US12/525,977 priority patent/US8263117B2/en
Priority to DE602008006684T priority patent/DE602008006684D1/de
Publication of WO2008096779A1 publication Critical patent/WO2008096779A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/81—Preparation or application process involves irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)

Abstract

　シクロデキストリンＣ７０錯体を含有する溶液と、リポソームを形成可能な脂質を含有する溶液とを１０～４５°Cで混合する。これにより、Ｃ７０フラーレンが本来有する物性を有し、安定に極性溶媒に溶解可能なＣ７０含有リポソームを製造することができる。これにより、本発明は、Ｃ７０フラーレンが本来有する物性を有し、安定に極性溶媒に溶解可能なＣ７０含有リポソームおよびその製造方法、並びにその利用を提供する。
PCT/JP2008/051928 2007-02-09 2008-02-06 Ｃ７０含有リポソームおよびその製造方法、並びにその利用 WO2008096779A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2008557136A JP5334170B2 (ja) 2007-02-09 2008-02-06 Ｃ７０含有リポソームおよびその製造方法、並びにその利用
AT08704499T ATE507835T1 (de) 2007-02-09 2008-02-06 C70 fulleren-enthaltendes liposom, verfahren zu seiner herstellung und seine verwendung
EP08704499A EP2123288B1 (en) 2007-02-09 2008-02-06 C70 fullerene-containing liposome, method for producing the same, and use of the same
US12/525,977 US8263117B2 (en) 2007-02-09 2008-02-06 C70-containing liposome, method for producing the same, and use of the same
DE602008006684T DE602008006684D1 (de) 2007-02-09 2008-02-06 C70 fulleren-enthaltendes liposom, verfahren zu seiner herstellung und seine verwendung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007031340 2007-02-09
JP2007-031340 2007-02-09

Publications (1)

Publication Number Publication Date
WO2008096779A1 true WO2008096779A1 (ja) 2008-08-14

Family

ID=39681685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051928 WO2008096779A1 (ja) 2007-02-09 2008-02-06 Ｃ７０含有リポソームおよびその製造方法、並びにその利用

Country Status (6)

Country Link
US (1) US8263117B2 (ja)
EP (1) EP2123288B1 (ja)
JP (1) JP5334170B2 (ja)
AT (1) ATE507835T1 (ja)
DE (1) DE602008006684D1 (ja)
WO (1) WO2008096779A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011057591A (ja) * 2009-09-08 2011-03-24 Fujifilm Corp リポソーム、並びに診断用造影剤、治療促進剤、及び医薬組成物
JP2012184199A (ja) * 2011-03-07 2012-09-27 Nara Institute Of Science & Technology フラーレン誘導体を用いた水溶性光増感性材料
JP2014508518A (ja) * 2011-02-15 2014-04-10 メリマック ファーマシューティカルズ， インコーポレイテッド 核酸を細胞へ送達する組成物及び方法
CN110408272A (zh) * 2019-07-05 2019-11-05 浙江大学 一种基于主客体作用制备光动力抗菌涂层的方法及其产品和应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9685600B2 (en) 2015-02-18 2017-06-20 Savannah River Nuclear Solutions, Llc Enhanced superconductivity of fullerenes
ES2862191T3 (es) 2015-07-22 2021-10-07 Nitto Denko Corp Composiciones y métodos para formas de liófilos de nanopartículas
EP3411008B1 (en) 2016-02-04 2023-05-17 The Cleveland Clinic Foundation Compositions comprising polyhydroxy fullerene sunscreen active agents
CN108904302B (zh) * 2018-08-02 2021-01-29 北京福纳康生物技术有限公司 水溶性富勒烯外用组合物
US11484508B2 (en) 2019-08-08 2022-11-01 Innovation for Success, LLC Dissolved C60 and method of producing dissolved C60
US10842742B1 (en) * 2019-08-08 2020-11-24 Innovation for Success, LLC Dissolved C60 and method of producing dissolved C60
US11400113B2 (en) 2019-08-08 2022-08-02 Innovation for Success, LLC Dissolved C60 and method of producing dissolved C60
CN113943676A (zh) * 2021-10-29 2022-01-18 济南紫金玫瑰股份有限公司 一种菌液的培养基
CN115040505B (zh) * 2022-06-24 2024-01-30 河南科技大学 一种光甘草定复合物及其制备方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0748302A (ja) 1993-07-30 1995-02-21 Tokyo Gas Co Ltd フラロールの合成方法
JPH08143478A (ja) 1994-11-18 1996-06-04 Otsuka Pharmaceut Co Ltd 磁気共鳴造影剤
JPH09235235A (ja) 1996-02-29 1997-09-09 Res Inst For Prod Dev 光線力学的治療用フラーレン−水溶性高分子結合体光増感剤
JP2004022424A (ja) 2002-06-19 2004-01-22 Japan Science & Technology Corp ホスト−ゲスト錯体を含有する光電変換素子用材料
JP2004250690A (ja) 2003-01-27 2004-09-09 Mitsubishi Corp 抗酸化組成物と外用組成物
JP2005225772A (ja) 2004-02-10 2005-08-25 Japan Science & Technology Agency 炭素化合物の封入された微小粒子の複合体
JP2005534718A (ja) 2002-06-26 2005-11-17 メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング カチオンキャリヤー系において診断化合物および治療化合物を安定化させる新規方法
JP2006069812A (ja) 2004-08-31 2006-03-16 Nara Institute Of Science & Technology フラーレンの水性化方法
JP2006124378A (ja) 2004-09-29 2006-05-18 Nof Corp 化粧料用リポソーム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004099293A (ja) 2002-09-12 2004-04-02 Matsushita Electric Ind Co Ltd 画像形成装置
EP1595936B1 (en) 2003-01-27 2011-10-19 Vitamin C60 Bioresearch Corporation Composition for external use
EP1672025B1 (en) 2003-10-10 2011-05-11 Japan Science and Technology Agency Finely particulate composite containing carbon compound encapsulated therein

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0748302A (ja) 1993-07-30 1995-02-21 Tokyo Gas Co Ltd フラロールの合成方法
JPH08143478A (ja) 1994-11-18 1996-06-04 Otsuka Pharmaceut Co Ltd 磁気共鳴造影剤
JPH09235235A (ja) 1996-02-29 1997-09-09 Res Inst For Prod Dev 光線力学的治療用フラーレン−水溶性高分子結合体光増感剤
JP2004022424A (ja) 2002-06-19 2004-01-22 Japan Science & Technology Corp ホスト−ゲスト錯体を含有する光電変換素子用材料
JP2005534718A (ja) 2002-06-26 2005-11-17 メディゲーネ オンコロギー ゲゼルシャフト ミット ベシュレンクテル ハフツング カチオンキャリヤー系において診断化合物および治療化合物を安定化させる新規方法
JP2004250690A (ja) 2003-01-27 2004-09-09 Mitsubishi Corp 抗酸化組成物と外用組成物
JP2005225772A (ja) 2004-02-10 2005-08-25 Japan Science & Technology Agency 炭素化合物の封入された微小粒子の複合体
JP2006069812A (ja) 2004-08-31 2006-03-16 Nara Institute Of Science & Technology フラーレンの水性化方法
JP2006124378A (ja) 2004-09-29 2006-05-18 Nof Corp 化粧料用リポソーム

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
IKEDA A. ET AL.: "An extremely effective DNA photocleavage utilizing functionalized liposomes with a fullerene-enriched lipid bilayer", J. AM. CHEM. SOC., vol. 129, no. 14, 20 March 2007 (2007-03-20), pages 4140 - 4141, XP008112463 *
IKEDA A. ET AL.: "Efficient photocleavage of DNA utilising water-soluble lipid membrane-incorporated [60]fullerenes prepared using a [60]fullerene exchange method", ORG. BIOMOL. CHEM., vol. 3, no. 16, 2005, pages 2907 - 2909, XP008112524 *
IKEDA A. ET AL.: "Konodo C60 Naiho Liposome no Shinchoseiho to Sono DNA Hikari Setsudanno no Hyoka", KOBUNSHI KAKO, vol. 55, no. 4, 2006, pages 180 - 184, XP003021973 *
IKEDA, T. ET AL., ORG. BIOMOL. CHEM., vol. 3, 2005, pages 2907 - 2909
K. KOMATSU ET AL., J. CHEM. SOC., 1999
MIYATA N. ET AL.: "Fullerene no Hikari Zokan Seibutsu Sayo ni Kan'yo suru Hanno Kasseishu no Kaiseki", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 120, no. 10, 2000, pages 1007 - 1016, XP008112527 *
See also references of EP2123288A4
WEI X. ET AL.: "New chemical method for selective generation of C70 'n-' (n=1,2,3) anions and formation and properties of an aqueous colloidal solution of C70", J. CHEM. SOC. PERKIN TRANS 2, no. 1, 1999, pages 121 - 126, XP008112479 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011057591A (ja) * 2009-09-08 2011-03-24 Fujifilm Corp リポソーム、並びに診断用造影剤、治療促進剤、及び医薬組成物
JP2014508518A (ja) * 2011-02-15 2014-04-10 メリマック ファーマシューティカルズ， インコーポレイテッド 核酸を細胞へ送達する組成物及び方法
JP2017093436A (ja) * 2011-02-15 2017-06-01 メリマック ファーマシューティカルズ， インコーポレイテッドＭｅｒｒｉｍａｃｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 核酸を細胞へ送達する組成物及び方法
US10087464B2 (en) 2011-02-15 2018-10-02 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
JP2012184199A (ja) * 2011-03-07 2012-09-27 Nara Institute Of Science & Technology フラーレン誘導体を用いた水溶性光増感性材料
CN110408272A (zh) * 2019-07-05 2019-11-05 浙江大学 一种基于主客体作用制备光动力抗菌涂层的方法及其产品和应用

Also Published As

Publication number Publication date
ATE507835T1 (de) 2011-05-15
US8263117B2 (en) 2012-09-11
DE602008006684D1 (de) 2011-06-16
EP2123288A4 (en) 2010-03-24
EP2123288B1 (en) 2011-05-04
EP2123288A1 (en) 2009-11-25
JP5334170B2 (ja) 2013-11-06
JPWO2008096779A1 (ja) 2010-05-20
US20100278885A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
WO2008096779A1 (ja) Ｃ７０含有リポソームおよびその製造方法、並びにその利用
WO2009120247A3 (en) Lipid nanoparticle compositions and methods of making and using the same
WO2009149253A3 (en) Mrna cap analogs
WO2009039307A3 (en) Hydrogels and methods for producing and using the same
EP2274081B8 (de) Cellulosehydrat-membran, verfahren zu ihrer herstellung und verwendung davon
WO2007077563A3 (en) Solid-fluid composition
WO2009038897A3 (en) Nanowire battery methods and arrangements
WO2009130649A3 (en) Plasma membrane vesicles and methods of making and using same
EP2131474A4 (en) Permanent magnet type rotator and process for producing the same
WO2010048585A3 (en) Oligomeric compounds and methods
WO2008073171A3 (en) Monodisperse single-walled carbon nanotube populations and related methods for providing same
WO2012154332A3 (en) Stable nanoparticles for highly saline conditions
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2008001292A3 (en) Multi-ply fibrous structures and products employing same
EP2165694B8 (en) Vesicle useful for external preparation for skin, and external preparation for skin comprising the vesicle
HK1139790A1 (en) Anisotropic conductive film, joined structure and method for producing the joined structure
WO2010011644A3 (en) Differentiated anucleated cells and method for preparing the same
WO2009102172A3 (ko) 콜린 알포세레이트 함유 약학 제제
WO2005019104A3 (en) Controlled nanotube fabrication and uses
WO2013030033A3 (en) Mixing apparatus for frozen products
WO2010091308A3 (en) Oligomeric compounds and methods
WO2009064681A3 (en) Liquid compositions comprising valsartan
WO2012097223A3 (en) Oligosaccharide conjugates for targeting bacteria and uses related thereto
WO2012151242A3 (en) Lignin-based nanostructures
WO2009009665A3 (en) O-desmethylvenlafaxine

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704499

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008557136

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12525977

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008704499

Country of ref document: EP